Relmada Therapeutics (RLMD) Earnings Date & Reports

Get AI intraday signals

A.I. Advisor

published Earnings

RLMD is expected to report earnings to fall 13.19% to -62 cents per share on March 25

Relmada Therapeutics RLMD Stock Earnings Reports

Q4'24

Est.

$-0.62

Q3'24

Missed

by $0.04

Q2'24

Beat

by $0.24

Q1'24

Beat

by $0.26

Q4'23

Missed

by $0.01

The last earnings report on November 07 showed earnings per share of -72 cents, missing the estimate of -68 cents. With 84.18K shares outstanding, the current market capitalization sits at 95.35M.

View a ticker or compare two or three

Compare

RLMD

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For RLMD
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

2222 Ponce de Leon Boulevard

Phone

+1 786 629-1376

Employees

Web

https://www.relmada.com